精神医学的共同研究及授权契约:2019年～2025年

《精神病学合作与许可交易》提供了前所未有的途径，可以全面了解全球领先的生物製药公司正在进行的精神病学交易。

这份经过全面修订和更新的报告提供了 2019 年至 2025 年 569 项精神病学交易的详细资讯。

此报告提供双方宣布的交易付款条款。这些数据为付款条款和其他贸易条款提供了有用的见解。

了解潜在合作伙伴谈判交易条款的弹性可以为谈判过程提供重要的见解，让您了解谈判条款时会发生什么。许多小型企业可能会想要详细的付款条款，但当涉及到如何产生付款以及如何转移权利时，细节决定成败。

本报告提供了当前协议交易和合作资料库中记录的自 2019 年以来宣布的合作和许可协议的综合列表，包括可用的财务条款，并包含公司及其合作伙伴向 SEC 提交的实际许可协议文件的在线副本链接。

本报告的第一部分描述了精神病学领域的贸易和商业活动。第 1 章对报告进行了介绍，第 2 章分析了精神病学领域的交易趋势。

第 3 章介绍精神医学领域已达成交易的财务条款以及发展阶段公告。交易按标题价值、预付款、里程碑付款和特许费率列出并分为几个部分。

第 4 章回顾了精神病领域交易最活跃的 25 家生物製药公司。对于美国证券交易委员会已公开宣布协议的案件，可以透过这些连结在当前协议交易和联盟资料库中线上存取该协议。

第 5 章对 2016 年以来签署和宣布的精神病学交易进行了全面深入的回顾，并提供合约文件。每个交易标题都透过网路连结连结到实际合约文件的线上版本，从而可以根据需要轻鬆存取每个文件。

第六章提供了按治疗目标分类的精神病病例的综合目录。

它也提供了大量图表和图形，展示了 2019 年及以后的精神病学交易趋势和活动。

此外，我们还提供按公司 A-Z 和技术类型组织的综合贸易目录。每个交易标题都提供了一个指向在线交易记录的网络链接，并在可用的情况下提供合同文件，从而允许根据需要轻鬆访问每个文件。

主要优点

精神医学合作研究和授权协议为读者提供了以下主要好处：

• 了解 2019 年及以后的合约趋势
• 查看精神科合作研究和许可机会
• 基准分析 - 确定交易的市场价值
• 财务条款 – 预付款、里程碑付款、特许权使用费
• 依公司 A-Z、治疗目标、技术类型划分的交易目录
• 大额交易金额
• 最活跃的交易者
• 确定每笔交易的资产和条款
• 查阅合约文件－洞察交易结构
• 尽职调查 - 评估拟议交易条款对合作伙伴公司的适用性。
• 节省数百小时的研究时间

研究范围

• 精神病学研究合作与许可协议旨在从全球领先的生物製药公司更深入地了解精神病学趋势和交易结构。

回报内容

• 生物製药产业精神医学领域的趋势
• 合作与授权交易结构概述
• 涵盖製药和生物技术的精神病学交易记录目录
• 重大精神医学交易
• 最活跃的精神科许可公司

目录

摘要整理

第1章 简介

第2章 精神医学的交易趋势

• 简介
• 长期的精神科合作关係
• 以交易类型划分的精神科合作关係
• 精神医学与产业界的合作（依领域）
• 根据发展阶段进行精神医学合作
• 按技术类型划分的精神科合作
• 基于治疗指征的精神科合作

第3章 精神医学的联盟的金钱的交易条件

• 简介
• 揭露精神医学合作的财务条款
• 精神科伙伴关係的核心价值
• 精神医学中的前期交易
• 精神医学交易中的里程碑付款
• 精神病专利费率

第4章 精神医学主要的交易和交易负责人

• 简介
• 精神科合作领域最活跃的公司
• 精神科领域最活跃的交易者名单
• 以价值为排名的顶级精神科交易

第5章 精神医学的契约文件名录

• 简介
• 已签约的精神科联盟契约

第6章 按治疗标的精神医学的交易

• 简介
• 按精神科治疗标的交易
• 交易名录
• 交易目录 - 2019 年至 2025 年精神科交易（依公司划分）
• 交易目录 - 按技术类型划分的精神病学交易（2019-2025 年）
• 定义交易类型
• 关于 Biopharma Research Ltd
• 当前合作伙伴关係
• 当前合约
• Current Partnering 的最新报告标题

Psychiatry Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the psychiatry deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of 569 psychiatry deals from 2019 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of psychiatry dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in psychiatry dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the psychiatry field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in psychiatry dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of psychiatry deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of psychiatry deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in psychiatry deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Psychiatry Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse psychiatry collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Psychiatry Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of psychiatry trends and structure of deals entered into by leading biopharma companies worldwide.

Psychiatry Collaboration and Licensing Deals includes:

• Trends in psychiatry dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of psychiatry deal records covering pharmaceutical and biotechnology
• The leading psychiatry deals by value
• Most active psychiatry licensing dealmakers

In Psychiatry Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Psychiatry Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in psychiatry dealmaking

• 2.1. Introduction
• 2.2. Psychiatry partnering over the years
• 2.3. Psychiatry partnering by deal type
• 2.4. Psychiatry partnering by industry sector
• 2.5. Psychiatry partnering by stage of development
• 2.6. Psychiatry partnering by technology type
• 2.7. Psychiatry partnering by therapeutic indication

Chapter 3 - Financial deal terms for psychiatry partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for psychiatry partnering
• 3.3. Psychiatry partnering headline values
• 3.4. Psychiatry deal upfront payments
• 3.5. Psychiatry deal milestone payments
• 3.6. Psychiatry royalty rates

Chapter 4 - Leading psychiatry deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in psychiatry partnering
• 4.3. List of most active dealmakers in psychiatry
• 4.4. Top psychiatry deals by value

Chapter 5 - Psychiatry contract document directory

• 5.1. Introduction
• 5.2. Psychiatry partnering deals where contract document available

Chapter 6 - Psychiatry dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by psychiatry therapeutic target
• Deal directory
• Deal directory - Psychiatry deals by company A-Z 2019 to 2025
• Deal directory - Psychiatry deals by technology type 2019 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Psychiatry partnering since 2019
• Figure 2: Psychiatry partnering by deal type since 2019
• Figure 3: Psychiatry partnering by industry sector since 2019
• Figure 4: Psychiatry partnering by stage of development since 2019
• Figure 5: Psychiatry partnering by technology type since 2019
• Figure 6: Psychiatry partnering by indication since 2019
• Figure 7: Psychiatry deals with a headline value
• Figure 8: Psychiatry deals with upfront payment values
• Figure 9: Psychiatry deals with milestone payment
• Figure 10: Psychiatry deals with royalty rates
• Figure 11: Active psychiatry dealmaking activity since 2019
• Figure 12: Top psychiatry deals by value since 2019